Compact Multi-Input Genetic Logic Gate for Precise Cell Targeting
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current gene therapy vectors face challenges with low efficacy, high toxicity, and long developmental timelines due to insufficient control over therapeutic gene expression, leading to unintended gene expression in non-target cell types and tissues, and dosage issues.
Innovation Solution
Engineering contiguous DNA molecules that encode complex multi-input genetic logic circuits capable of probing multiple transcription factors and microRNA features, allowing for precise targeting of specific cell types or states both in vivo and in vitro, using various viral and non-viral delivery vectors.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If current gene therapy vectors are used, then therapeutic gene delivery is achieved, but gene expression occurs in unintended cell types and tissues with insufficient control
Solution Approach 1:
The patent divides the gene therapy vector into modular components: multiple input sensors (promoter/response element modules) that detect specific cellular features, a logic processing unit (genetic logic circuit) that integrates signals, and an output module that delivers therapeutic action. Each module can be independently designed and optimized, allowing complex cell-type specificity to be built from simple, reliable building blocks.
Solution Approach 2:
The patent introduces transactivators as intermediary molecules that mediate between input sensors and the output therapeutic gene. These transactivators are conditionally activated only when specific combinations of cellular features are detected, serving as a buffer that translates complex cellular states into controlled gene expression decisions without requiring direct complex regulatory interactions.
2Reliability
If gene expression control is relaxed, then therapeutic efficacy increases, but toxicity increases due to expression in non-target cells
Solution Approach 1:
The patent applies local quality by making the gene expression control system highly specific to particular cell types through customized logic circuits. Each therapeutic vector can be programmed with cell-type-specific input sensors and logic rules, allowing the same therapeutic gene to be expressed at high levels in target cells while remaining completely silent in non-target cells, thus achieving high efficacy without off-target toxicity.
Solution Approach 2:
The patent changes the control parameters from simple presence/absence of a single promoter to multi-parameter detection using multiple transcription factor response elements and microRNA target sites. This allows the system to distinguish between different cell types based on combinatorial patterns of cellular features, enabling selective high-level expression only in the desired cell type while maintaining low expression elsewhere.
3Manufacturing precision
If multi-input logic circuits are implemented, then precise cell targeting is achieved, but vector packaging capacity is exceeded
Solution Approach 1:
The patent creates universal, reusable genetic parts that can be combined to build different logic circuits. Standardized promoter modules, response elements, and transactivator systems can be mixed and matched to create cell-type-specific logic circuits without requiring entirely new sequences for each application. This modularity reduces the overall DNA payload required for precise targeting.
Solution Approach 2:
The patent implements nested genetic structures where smaller functional elements are embedded within larger regulatory frameworks. For example, multiple transcription factor response elements are nested within a single promoter region, and multiple microRNA target sites are embedded within the 3' UTR of a single transcript. This nesting allows complex multi-input logic to be encoded in a compact DNA sequence that fits within viral packaging capacity.
Data Source
AI summary
Disclosed herein are contiguous DNA sequences encoding highly compact multi-input genetic logic gates for precise in vivo cell targeting, and methods of treating disease using a combination of in vivo delivery and such contiguous DNA sequences.